Amlodipine-Induced Gingival Hyperplasia in a Great Dane

2011 ◽  
Vol 47 (5) ◽  
pp. 375-376 ◽  
Author(s):  
Marlene S. Pariser ◽  
Paul Berdoulay

A 3 yr old, 70 kg (154 lbs) female spayed Great Dane developed gingival hyperplasia after treatment of systemic hypertension with amlodipine 7.5 mg q 12 hr for 16 mo. Physical examination was unremarkable except for systemic hypertension and severe gingival hyperplasia. Amlodipine was replaced with hydralazine (0.72 mg/kg [0.32 mg/lb]). Nine months later, gingival hyperplasia was nearly resolved and hypertension was well controlled. Calcium channel blockers such as amlodipine are a rare cause of gingival hyperplasia in the canine patient. Recognition of this side effect is important because a full recovery can be achieved when the offending agent is removed.

2021 ◽  
Vol 16 ◽  
Author(s):  
Suryanarayana Challa Reddy ◽  
Naresh Midha ◽  
Vivek Chhabra ◽  
Deepak Kumar ◽  
Gopal Krishna Bohra

Background: DIGO or drug-induced gingival overgrowth occurs as a side effect of certain drugs. Until now, the etiology of drug-induced gingival overgrowth is not clearly understood. Among the calcium channel blockers, nifedipine has been shown to be most frequently associated with drug-induced gingival hyperplasia. Amlodipine is a comparatively newer calcium channel blocker that witha longer duration of action and lesser side effects as compared to nifedipine. There are only certain case reports of amlodipine-induced gum hyperplasia. Case presentation: We report a case of amlodipine-induced gum hyperplasia in a 66-year-old hypertensive patient taking amlodipine at a dose of 5 mg once a day. There was significant regression of gum hypertrophy after substitution of amlodipine by Losartan. Conclusion: Amlodipine is one of the commonly prescribed antihypertensive drugs, and gingival hyperplasia is one overlooked side effect in patients taking amlodipine. Awareness of this potential side effect of amlodipine may be helpful to reduce the anxiety of patients and the cost of diagnostic procedures.


2000 ◽  
Vol 14 (2) ◽  
pp. 155-156 ◽  
Author(s):  
GG Missouris ◽  
RG Kalaitzidis ◽  
FP Cappuccio ◽  
GA MacGregor

1986 ◽  
Vol 58 (1) ◽  
pp. 157-160 ◽  
Author(s):  
William H. Frishman ◽  
Shlomo Charlap ◽  
Eric L. Michelson

1986 ◽  
Vol 57 (7) ◽  
pp. D22-D29 ◽  
Author(s):  
William H. Frishman ◽  
Shlomo Charlap ◽  
Bruce Kimmel ◽  
Jeffrey Goldberger ◽  
George Phillippides ◽  
...  

2009 ◽  
Vol 11 (2) ◽  
pp. 111-111 ◽  
Author(s):  
Costas Fourtounas ◽  
Jannis G. Vlachojannis

2010 ◽  
Vol 37 (7) ◽  
pp. 625-630 ◽  
Author(s):  
Gaganpreet Kaur ◽  
Katia M. C. Verhamme ◽  
Jeanne P. Dieleman ◽  
Ann Vanrolleghem ◽  
Eva M. Van Soest ◽  
...  

1994 ◽  
Vol 43 (2) ◽  
pp. 115-118 ◽  
Author(s):  
A. Nyska ◽  
M. Shemesh ◽  
H. Tal ◽  
D. Dayan

2007 ◽  
Vol 1 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Vishaka Grover ◽  
Anoop Kapoor ◽  
C.M. Marya

ABSTRACT Calcium channel blockers are one of the most commonly used drugs for the management of cardiovascular disorders and are known for causing gingival over growth as adverse effects. Now a days, a new drug in this family Amlodipine, is being widely used, because of its duration of action. But it is of concern to the dental practitioner that this drug too has a similar effect on gingival tissues. This paper aims at drawing the attention of dentists towards the adverse effects of amlodipine along with providing a brief review of the pharmacologic profile of this drug, its effects on the gingiva and the management of hyperplasia.


Sign in / Sign up

Export Citation Format

Share Document